New Technology Add on Payment

New Technology Add-On Payment (NTAP) is a special payment mechanism from the Centers for Medicare & Medicaid Services (CMS) that provides temporary supplemental reimbursement for new medical technologies used in the inpatient hospital setting.

NTAP was designed to bridge the gap between FDA approval and long-term reimbursement by offsetting the cost of breakthrough or high-cost technologies that are not yet adequately reflected in existing MS-DRG payments.

At Lonsberry Consulting™, we guide you through the complex and high-stakes NTAP process—from economic justification to CMS submission—ensuring your innovation not only gets approved, but also gets paid for.

✅ Provides up to 65% of the cost of your technology on top of the DRG
✅ Helps hospitals adopt early without losing money
✅ Increases CMS visibility for long-term coverage consideration
✅ Signals innovation and value to commercial payers and investors
✅ Extends your pricing runway while pursuing permanent coding or coverage

With firsthand experience leading NTAP submissions and approvals, Lonsberry Consulting™ helps you:

• Evaluate NTAP eligibility and timing
• Build cost and clinical justifications for CMS reviewers
• Develop the full NTAP application, including ICD-10-PCS code requests
• Coordinate clinical, regulatory, and economic evidence for maximum impact
• Avoid rejections due to timing, coding gaps, or insufficient data

The NTAP process doesn't start after FDA approval—it starts before you even finalize your clinical trial design. Our PRECODE™ System helps you align your evidence, endpoints, and coding strategy from the very beginning, giving you the strongest possible position to secure NTAP and sustain long-term payment.

• Inpatient devices or biologics with FDA clearance or approval
• Technologies with Breakthrough Device Designation (BDD)
• Innovations not yet fully reflected in DRG pricing
• Companies preparing for commercial launch within 1–2 years

NTAP can be a game-changer—but it’s also competitive, time-sensitive, and data-driven. Most companies that fail to receive NTAP do so because they approached it too late or without a strategic evidence plan.

We help you de-risk the process, meet CMS expectations, and bring your innovation to hospitals with confidence and coverage.